arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Senti Biosciences Holdings, Inc.

SNTI

$0.16 ▼ -0.01 (-7.90%) at close

6 Visible periods

22 Metrics

Absolute Benchmarks

Price Chart

Health

Weak

Bearish Absolute basis

auto_awesome

Analytical Summary

On an absolute basis, Senti Biosciences Holdings, Inc. shows weak fundamentals, weighed down by Return on Invested Capital and FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $3.6M

Dividend Yield —

Revenue Growth None

Op. Margin —

ROIC -972.2% ↘

FCF / Share $-1.94 ↗

Trailing P/E —

Price / Book 0.9x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

6-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$22.00K

— —

Net Income Profit after all expenses

$-61.44M

↓ -16.4% —

FCF / Share Free cash flow per share

$-1.94

↑ +78.5% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Invested CapitalReturn on Invested Capital of -972.2% is weak on an absolute basis (target > 10%)
FCF / Net IncomeFCF / Net Income of 0.71x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Feb 28, 2021 10-K ↗
Revenue Growth YoY (%)	—	N/M	-40.2% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-603%)	55.2% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+590%)	—	—
EPS Growth YoY (%)	77.3% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	24.9% Good ↓ Good Declining Year-over-year change in earnings per share Optimal: > 10%	28.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	88.3% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-16.4% Weak ↓ Weak Declining Year-over-year change in net income	25.7% Excellent ↑ Excellent Improving Year-over-year change in net income	-22.1% Weak Weak Year-over-year change in net income	-5.2% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	78.5% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	37.9% Excellent ↓ Excellent Declining Year-over-year change in free cash flow	50.3% Excellent Excellent Year-over-year change in free cash flow	78.8% Excellent Excellent Year-over-year change in free cash flow	—	—
Revenue CAGR 3Y (%)	-82.7% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Feb 28, 2021 10-K ↗
FCF / Net Income (x)	0.71x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.31x Good Good Free cash flow relative to reported net income Optimal: > 1x	0.73x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Feb 28, 2021 10-K ↗
Return on Invested Capital (%)	-972.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-188.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-109.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-38.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	28.7% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-134.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-62.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-77.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-34.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	-41.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	—	-205.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1472%)	-106.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-808%)	-45.7% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-405%)	49.6% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+231%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Feb 28, 2021 10-K ↗
Net Debt (USD)	$-16.42M	$-48.28M	$-35.93M	$-57.62M	$-56.03M	$0.00

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Feb 28, 2021 10-K ↗
Revenue per Share (USD)	$0.00	$0.00	$0.58	$1.64	$9.48	—
Basic EPS, GAAP (USD)	$-2.73	$-12.03	$-16.01	$-22.30	$-190.00	—
Free Cash Flow per Share (USD)	$-1.94	$-9.01	$-14.52	$-29.21	$-137.96	—
Book Value per Share (USD)	$0.18	$5.31	$14.64	$28.88	$-374.97	—
Tangible Book Value per Share (USD)	$0.18	$5.31	$14.64	$28.88	$-374.97	—
Basic Weighted Avg Shares (shares)	22.48M	4.60M	4.44M	2.61M	291,228	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Feb 28, 2021 10-K ↗
Working Capital (USD)	$9.30M	$45.81M	$58.53M	$84.53M	$45.65M	—
Total Equity (USD)	$5.59M	$25.65M	$66.91M	$127.26M	$-111.46M	$0.00

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Feb 28, 2021 10-K ↗
Sales/Revenue/Turnover (USD)	$22.00K	$0.00	$2.56M	$4.29M	$2.76M	—
Depreciation Expense (USD)	$3.64M	$3.84M	$3.56M	$1.40M	$769.00K	—
Net Income, GAAP (USD)	$-61.44M	$-52.79M	$-71.06M	$-58.21M	$-55.32M	—
Operating Cash Flow (USD)	$-43.44M	$-41.40M	$-52.40M	$-34.90M	$-34.63M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 6 years · 23 quarters

Senti Biosciences Holdings, Inc.

Analytical Summary

6-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Benchmarks unavailable

Compare SNTI with peers